NOT-AI-22-035
NIH
The purpose of the proposed Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. These services may also be used to support product discovery and development leading to IND, Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The focus of these contracts will be development of therapeutics and prevention products for HIV, including single or combination products with activity against associated co-infections such as Mycobacterium tuberculosis or MPTs that incorporate contraceptives. At the discretion of NIAID, these contracts may also be used to advance therapeutic and preventive strategies for other infectious diseases. Throughout this Statement of Work (SOW), these candidate products and/or strategies will collectively be referenced as “products.”
